Alemtuzumab Induction in Renal Transplantation

Abstract

By the first year after transplantation, biopsy-confirmed acute rejection was less frequent with alemtuzumab than with conventional therapy. The apparent superiority of alemtuzumab with respect to early biopsy-confirmed acute rejection was restricted to patients at low risk for transplant rejection; among high-risk patients, alemtuzumab and rabbit antithymocyte globulin had similar efficacy. (Funded by Astellas Pharma Global Development; INTAC ClinicalTrials.gov number, NCT00113269.).

Modern Immunosuppression Regimens in Kidney Transplantation

“…In the study by Hanaway et al, acute rejection rates were relatively low in low-risk patients receiving alemtuzumab compared to basiliximab, although the reduced immunologic risk profile of alemtuzumab was not evident in high risk patients treated with rATG [54]. The overall rate of adverse events with alemtuzumab was similar to that of basiliximab or rATG over the 3 year study period (53% versus 50%, respectively; p=0.46).…”

“…In a recent study, alemtuzumab was prospectively compared to basiliximab and rATG as an induction agent in patients on a steroid-sparing immunosuppressive regimen [54]. Alemtuzumab demonstrated lower short-term rates of acute rejection compared to basiliximab in patients at low-risk of developing acute rejection.…”

Tailor-Made Induction Therapy in ‘Low Risk’ Renal Transplants; A South Asian Perspective

“…Alemtuzumab is a mAb originally produced for treatment to basiliximab in 'low risk' transplants, without any observed advantage in graft or patient survival [42]. In the 'high risk' patients, alemtuzumab showed no signifi cant advantage over rATG.…”

Induction Therapy in Renal Transplant Recipients

“…Because its efficacy is greatest against naïve T cells, its use in sensitized patients may-be limited. In a recent study, alemtuzumab was prospectively compared to basiliximab and rATG as an induction agent in patients on a steroid-sparing immunosuppressive regimen (Hanaway et al, 2011). Alemtuzumab demonstrated lower short-term rates of acute rejection compared to basiliximab in patients at low-risk of developing acute rejection.…”